Showing 31-40 of 119 results for "".
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new study in the New England…
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and second This allows providers to combine TargetCool with other needle-…
- Spotlight on: Lanolin Allergenicityhttps://practicaldermatology.com/news/spotlight-on-lanolin-allergenicity/2461531/The phenomenon of lanolin allergenicity is the focus of the Contact Allergen of the Year article in Dermatitis. Lanolin and its derivatives are widely used in cosmetics and pharmaceuticals designed for topical use on skin, lips, nails, and hair, and as an ocular emollient. They also have many ind…
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative…
- FDA Grants Fast Track Designation for Union’s Oral Orismilast for Moderate to Severe HShttps://practicaldermatology.com/news/fda-grants-fast-track-designation-for-unions-oral-orismilast-for-the-treatment-of-moderate-to-severe-hs/2461493/The US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS). The FDA's Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditi…
- Rocatinlimab Shows Promise in ADhttps://practicaldermatology.com/news/rocatinlimab-shows-promise-in-ad/2461465/Rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results in atopic dermatitis patients both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. Rocatinlimab inhibits OX40—an immune molecule invol…
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling path…
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor Kim Jeehwan's engineering research …
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent eight treatment sessions with the 595 nm PD…
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropriate dose regimen for Phase 3 studies. In No…